Short bowel syndrome

Jun 18, 2020

Parenteral Nutrition Market to Reach Valuation of ~USD 8.4 Billion by the End of the Forecast Period 2019 to 2027: TMR

Jan 07, 2020

VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare Diseases

May 17, 2019

Therachon to Present Data from Ongoing Phase II Study of Apraglutide for Short Bowel Syndrome (SBS) at Digestive Disease Week

May 17, 2019

U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)

Mar 25, 2019

Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

Jan 16, 2019

Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome

Oct 09, 2018

Therachon Expands Rare Disease Pipeline with Acquisition of GLyPharma Therapeutic Inc.

Jun 09, 2017

Short Bowel Syndrome Market Growing at a CAGR of 25.53% During 2017 to 2021 Says a New Report at ReportsnReports.com